New
AOD-9604
44,99 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Targeted fat loss without IGF-1-mediated growth effects.
- No effect on blood glucose or insulin sensitivity.
- Fat reduction is well tolerated in patients with metabolic disorders and diabetes.
- It supports body recomposition when combined with exercise.
- Being investigated for cartilage repair (TGA approval in Australia for OA).
Description
AOD-9604
Fat Loss / Metabolism
MECHANISM OF ACTION
Modified C-terminal fragment of HGH (residues 176–191) with a Tyr substitution at position 177. It activates β3-adrenergic receptors to stimulate lipolysis in adipocytes, inhibits the activity of lipogenic enzymes, and does not activate IGF-1R or alter insulin/glucose dynamics.
KEY BENEFITS
- Targeted fat loss without IGF-1-mediated growth effects.
- No effect on blood glucose or insulin sensitivity.
- Fat reduction is well tolerated in patients with metabolic disorders and diabetes.
- It supports body recomposition when combined with exercise.
- Being investigated for cartilage repair (TGA approval in Australia for OA).
SIDE EFFECTS AND SAFETY
Minimal. Occasional reaction at the injection site. No cases of glucose dysregulation have been reported.
RESEARCH AND CLINICAL NOTES
Approved by the TGA as a new food additive in Australia (Metablose). Human trials demonstrated a statistically significant reduction in body fat compared to placebo over 12 weeks. Its mechanism of action differs from that of full-length HGH.
TARGET PROFILE:
Weight management, diabetic patients seeking fat loss without the side effects associated with GH, and body recomposition programs.
Additional information
| Weight | ,26 kg |
|---|
Related products
New
BPC 5 mg + TB 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Faster soft tissue repair than with any of the peptides alone.
- Coverage for localized repair (BPC-157) and systemic repair (TB-500).
- Reduction of inflammation and pain following an injury.
- Recovery of joints, tendons, ligaments, and muscles.
- A convenient, single-vial protocol for injury recovery.
New
GHK-Cu
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A significant increase in collagen synthesis and improved skin firmness.
- Accelerated healing and reduced scarring.
- Stimulation of the hair follicle and improvement in hair density.
- Systemic anti-aging effect through modulation of gene expression.
- Systemic antioxidant and anti-inflammatory action.
- Bone Regeneration and Nerve Repair in Research Models.
Glutathione
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Comprehensive reduction of oxidative stress.
- Improved Phase II hepatic detoxification.
- Supports the immune system.
- Skin lightening through the inhibition of melanin synthesis.
- Neuroprotection in Parkinson's disease and other degenerative conditions.
- Improving Insulin Sensitivity in Metabolic Research.
New
KPV
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Powerful anti-inflammatory action in the intestines for IBD, Crohn's disease, and colitis.
- Restoration of intestinal barrier function in intestinal permeability protocols.
- Systemic anti-inflammatory effect without immunosuppression.
- Supports healing and reduces skin inflammation.
- Oral bioavailability for administration targeted at the gastrointestinal tract.
- Safe: extremely low molecular weight and no systemic toxicity.
New
PT-141
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sexual desire in men and women.
- Improvement of erectile function via the central nervous system.
- Approved by the FDA for HSDD in premenopausal women as Vyleesi.
- Effective in patients who do not respond to PDE5 inhibitors.
- It can be used as needed, 45–90 minutes before the activity.
SS-31
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Restoration of mitochondrial function in aged and diseased tissues.
- Improved cardiac function in heart failure.
- Renal protection in ischemia-reperfusion injury.
- Reduction of neuroinflammation.
- Preservation of Muscle Fiber in Aging and Sarcopenia.
- FDA Breakthrough Therapy Designation for Barth Syndrome.
New
TB500
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Systemic repair and regeneration of soft tissues.
- Accelerated wound healing and scar reduction.
- Improved tissue flexibility and reduced inflammation.
- Cardiac protection and myocardial repair.
- Eye repair in research on corneal regeneration.
- Protection of renal podocytes.
New
Tesamorelin
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- FDA Approves Treatment to Reduce Visceral Fat Associated with HIV.
- Significant reduction in visceral fat in clinical trials.
- Improvement in lipid profile and metabolic health.
- Preservation of GH's natural pulsatile physiology.
- Cognitive Benefits: IGF-1 Modulation in Research on Mild Cognitive Impairment.
